Nothing Special   »   [go: up one dir, main page]

ATE333501T1 - Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps) - Google Patents

Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)

Info

Publication number
ATE333501T1
ATE333501T1 AT98942011T AT98942011T ATE333501T1 AT E333501 T1 ATE333501 T1 AT E333501T1 AT 98942011 T AT98942011 T AT 98942011T AT 98942011 T AT98942011 T AT 98942011T AT E333501 T1 ATE333501 T1 AT E333501T1
Authority
AT
Austria
Prior art keywords
vlps
particles
reassembly
papillomavirus virus
papillomavirus
Prior art date
Application number
AT98942011T
Other languages
English (en)
Inventor
Michael P Mccarthy
Joann Suzich
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Application granted granted Critical
Publication of ATE333501T1 publication Critical patent/ATE333501T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/802Virus-based particle
    • Y10S977/803Containing biological material in its interior
    • Y10S977/804Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98942011T 1997-09-05 1998-08-19 Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps) ATE333501T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05

Publications (1)

Publication Number Publication Date
ATE333501T1 true ATE333501T1 (de) 2006-08-15

Family

ID=25449564

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942011T ATE333501T1 (de) 1997-09-05 1998-08-19 Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)

Country Status (16)

Country Link
US (2) US6416945B1 (de)
EP (2) EP1015561B1 (de)
JP (2) JP4199416B2 (de)
AT (1) ATE333501T1 (de)
AU (1) AU742409B2 (de)
CA (1) CA2302545C (de)
CY (2) CY1107987T1 (de)
DE (3) DE69835294T2 (de)
DK (1) DK1015561T3 (de)
ES (2) ES2572628T3 (de)
FR (1) FR07C0012I2 (de)
HK (1) HK1030797A1 (de)
LU (1) LU91314I2 (de)
NL (1) NL300264I2 (de)
PT (1) PT1015561E (de)
WO (1) WO1999013056A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
CA2257822A1 (en) * 1996-07-17 1998-01-22 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Infectious papillomavirus pseudoviral particles
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
ES2325053T3 (es) * 1999-12-09 2009-08-25 Medimmune, Llc Metodo in vitro para desensamblaje/reensamblaje de particulas similares a virus de papilomavirus (vlp).
EP1305039B1 (de) * 2000-07-06 2008-12-31 Georgetown University Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
JP4746819B2 (ja) * 2000-09-18 2011-08-10 メディミューン,エルエルシー ワクチンの免疫原性を測定する試験管内検定
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
EA200701633A1 (ru) 2002-12-20 2007-12-28 Глаксосмитклайн Байолоджикалс С.А. Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
US20080131928A1 (en) 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
CN101287489A (zh) * 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
SG179488A1 (en) 2007-03-14 2012-04-27 Ligocyte Pharmaceuticals Inc Virus like particle purification
AU2008279584A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US8394411B2 (en) 2007-05-08 2013-03-12 The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health Papillomavirus pseudoviruses for detection and therapy of tumors
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
CA2768172A1 (en) 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
WO2011000058A1 (en) * 2009-07-03 2011-01-06 The University Of Queensland A method of preparation of a biological particulate structure
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
DK3046583T3 (da) 2013-09-18 2019-05-20 Aura Biosciences Inc Viruslignende partikelkonjugater til behandling af tumorer
EP3191505A2 (de) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Überlegene antigenen des menschlichen papillomvirus mit überlegenen immunologischen eigenschaften und impfstoff damit
RU2677336C2 (ru) * 2014-12-26 2019-01-16 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
JP2018536434A (ja) 2015-10-30 2018-12-13 アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. 腫瘍形質導入のための組成物及び方法
EP3368559A4 (de) 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. Zusammensetzungen und verfahren zur behandlung von krebs
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
KR20200084883A (ko) 2017-11-06 2020-07-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
JP2021502822A (ja) 2017-11-14 2021-02-04 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー.ファオ. in vitro及びin vivoでの遺伝子送達のための非ヒトパピローマウイルス
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたvlpワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
ES2572628T3 (es) 2016-06-01
JP4199416B2 (ja) 2008-12-17
NL300264I1 (nl) 2007-05-01
US6416945B1 (en) 2002-07-09
DE122007000015I1 (de) 2007-05-24
PT1015561E (pt) 2006-11-30
JP2009057377A (ja) 2009-03-19
FR07C0012I1 (de) 2007-03-30
LU91314I9 (de) 2019-01-30
NL300264I2 (nl) 2008-06-02
DE69835294T2 (de) 2007-07-26
HK1030797A1 (en) 2001-05-18
CA2302545C (en) 2012-04-03
CY2007007I1 (el) 2009-11-04
LU91314I2 (fr) 2007-04-23
EP1700911B1 (de) 2016-04-06
EP1700911A1 (de) 2006-09-13
DE69835294D1 (de) 2006-08-31
EP1015561A1 (de) 2000-07-05
WO1999013056A1 (en) 1999-03-18
CY1107987T1 (el) 2011-04-06
DK1015561T3 (da) 2006-11-13
FR07C0012I2 (fr) 2007-10-26
JP4486142B2 (ja) 2010-06-23
AU9015498A (en) 1999-03-29
CA2302545A1 (en) 1999-03-18
DE122007000015I2 (de) 2008-01-24
JP2001515922A (ja) 2001-09-25
ES2268787T3 (es) 2007-03-16
EP1015561B1 (de) 2006-07-19
AU742409B2 (en) 2002-01-03
CY2007007I2 (el) 2016-10-05
US6261765B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
ATE333501T1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
AU5998400A (en) In vitro reconstitution of segmented negative-strand rna viruses
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ATE296111T1 (de) Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
GEP20084431B (en) Papilloma virus vaccine
DE69721840D1 (en) Zuckerrohr bacilliformviruspromotor
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
AU2051888A (en) Novel process for purification of hepatitis a virions
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
HK1045149A1 (en) Process to separate 1,3-propanediol or glycerol, or a mixture thereof from a biological mixture.
DK0698668T3 (da) Fremgangsmåde til fremstilling af L-leucin
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
RU93019436A (ru) Способ получения человеческого лейкоцитарного интерферона